Anúncio
Anúncio

ATHA

ATHA logo

Athira Pharma, Inc. Common Stock

6.75
USD
Patrocinado
-0.44
-6.12%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

6.89

+0.14
+2.07%

Relatórios de Lucros ATHA

Rácio de surpresa positiva

ATHA separação 15 de 21 últimas estimativas.

71%

Próximo Relatório

Data do Próximo Relatório
25 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.87
Mudanças implicadas de Q3 25 (Revenue/ EPS)
--
/
-48.21%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
--
/
-77.69%

Athira Pharma, Inc. Common Stock earnings per share and revenue

On 06 de nov. de 2025, ATHA reported earnings of -1.68 USD per share (EPS) for Q3 25, missing the estimate of -1.24 USD, resulting in a -35.00% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -3.99% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 4 analistas forecast an EPS of -0.87 USD, with revenue projected to reach -- USD, implying an diminuir of -48.21% EPS, and aumentar of 0.00% in Revenue from the last quarter.
FAQ
For Q3 2025, Athira Pharma, Inc. Common Stock reported EPS of -$1.68, missing estimates by -35%, and revenue of $0.00, 0% as expectations.
The stock price moved down -3.99%, changed from $4.01 before the earnings release to $3.85 the day after.
The next earning report is scheduled for 25 de fev. de 2026.
Based on 4 analistas, Athira Pharma, Inc. Common Stock is expected to report EPS of -$0.87 and revenue of -- for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio